We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.755 | -2.87% | 25.515 | 26.37 | 25.45 | 26.34 | 17,676,600 | 17:13:16 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Pfizer Inc. and OPKO Health Inc. on Friday said the European Medicines Agency validated for review their marketing authorization application for somatrogon, a once-weekly human-growth hormone for pediatric patients with growth-hormone deficiency.
New York drug maker Pfizer said somatrogon, if approved, would help reduce the burden of daily growth-hormone injections, adding that it expects a decision from the European Commission in 2022.
Pfizer and OPKO, a Miami healthcare-services company, signed a worldwide agreement in 2014 to develop and commercialize somatrogon for growth-hormone deficiency. The U.S. Food and Drug Administration in January accepted for review the companies' application for somatrogon.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 26, 2021 07:30 ET (12:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
